Envestnet Asset Management Inc. Has $85.10 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Envestnet Asset Management Inc. increased its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 15.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 482,680 shares of the medical research company's stock after acquiring an additional 66,169 shares during the quarter. Envestnet Asset Management Inc. owned about 0.27% of IQVIA worth $85,096,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Sowell Financial Services LLC bought a new position in IQVIA during the first quarter valued at $305,000. Mather Group LLC. lifted its position in shares of IQVIA by 83.5% during the first quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after buying an additional 350 shares during the last quarter. Park Avenue Securities LLC grew its holdings in IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock worth $956,000 after purchasing an additional 1,562 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in IQVIA by 34.5% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock valued at $2,338,000 after buying an additional 3,398 shares in the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in shares of IQVIA by 57.0% in the fourth quarter. Jones Financial Companies Lllp now owns 1,215 shares of the medical research company's stock worth $239,000 after buying an additional 441 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Trading Down 1.7%

IQV stock traded down $2.80 during midday trading on Friday, reaching $162.73. The company's stock had a trading volume of 1,156,699 shares, compared to its average volume of 1,808,476. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 2.19. The stock has a market cap of $28.15 billion, a PE ratio of 16.04, a price-to-earnings-growth ratio of 1.84 and a beta of 1.30. The business's 50-day simple moving average is $151.77 and its 200-day simple moving average is $172.43. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The company had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same period in the previous year, the company posted $2.54 earnings per share. The company's quarterly revenue was up 2.5% compared to the same quarter last year. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of analyst reports. HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. Citigroup reissued a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Evercore ISI increased their price objective on IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday. Hsbc Global Res downgraded shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Finally, Redburn Partners set a $188.00 price objective on IQVIA in a research report on Friday, May 23rd. Eight research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $222.45.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.